Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 14 Apr 2023
In a new study, researchers found that PET-CT is better than contrast-enhanced CT as a predictor of survival in patients with metastatic breast cancer...
Read Full NewsPsychotropics are associated with increased BMI, and users with a high BMI genetic risk score and an unhealthy lifestyle have triple the risk for CVD, new research shows.
Tafasitamab and lenalidomide are likely to be approved with R-CHOP for frontline DLBCL, but with bispecific antibodies on the horizon, the role of the combination is uncertain.
In a phase 3 trial of patients with dedifferentiated liposarcoma, the CDK4/6 inhibitor extended progression-free survival more than sixfold.
A phase 3 trial evaluates a PARP inhibitor or placebo plus an androgen pathway inhibitor to treat men with advanced prostate cancer associated with genetic changes.
In the first phase 3 trial of teclistamab monotherapy, the bispecific antibody was associated with better PFS and OS than standard regimens in relapsed or refractory multiple myeloma.
A phase 3 trial evaluates the safety and efficacy of an investigational bispecific antibody with chemotherapy compared to standard treatment in advanced squamous NSCLC.
In an interim analysis of a randomized phase 2 trial, asandeutertinib improved intracranial response and intracranial PFS vs osimertinib in patients with EGFR-mutated NSCLC with brain metastases.
1.
'Next Berlin Patient' Adds to Small but Growing Number of People Cured of HIV
2.
Aspirin for CRC Risk Reduction May Benefit Unhealthy People Most
3.
New tumor therapy approach reduces costs and side effects while increasing accessibility
4.
Through the activation of bitter taste receptors, lidocaine has the potential to kill some cancer cells.
5.
Top Options Are Discovered Through Direct Comparison of 25 Migraine Drugs.
1.
Unlocking the Mystery of Hemoglobin C Trait: A Closer Look at a Rare Blood Disorder
2.
Refractory Iron Deficiency Anemia in a Young Adult: Diagnostic Challenges
3.
Understanding Mesenteric Masses: Symptoms, Diagnosis, and Treatment Options
4.
Unmasking the Hidden Symptoms of Ovarian Cancer
5.
Exploring New Treatment Options for Hemophilia: A Journey into the Unknown
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part X
2.
The Landscape of First-Line Treatment for Urothelial Carcinoma- Further Discussion
3.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion
4.
Understanding the Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- PALOMA 2 Study.
5.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge